Erlotinib Versus Gefitinib for Brain Metastases in Asian Patients with Exon 19 EGFR-mutant Lung Adenocarcinoma: a Retrospective, Multicenter Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2018 Nov 22

PMID 30458751

Citations 2

Authors

Ye Jiang

Jing Zhang

Juanjuan Huang

Bo Xu

Ning Li

Lei Cao

Mingdong Zhao

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to compare clinical outcomes of Erlotinib versus Gefitinib in the treatment of Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and newly diagnosed brain metastases.

Methods: Consecutive Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and newly diagnosed brain metastases were identified and initially received peroral administration of 150 mg/d erlotinib or 250 mg/d gefitinib during 2009-2015. Overall survival (OS) was the primary endpoint. Progression-free survival (PFS) was the second endpoint.

Results: The cohort consisted of 227 Asian patients (erlotinib-treated cohort: n = 112, mean age = 58.5 years [SD: 20.13]; gefitinib-treated cohort: n = 115, mean age = 58.4 years [SD: 19.52]). In a multivariate analysis controlling for age, sex and time span of smoking history, significant difference was detected in the 36-month OS between erlotinib and gefitinib groups (58.3% vs. 49.1%, p = 0.012). There was also significant difference in the 36-month PFS between erlotinib and gefitinib groups (64% vs. 53%, p = 0.013).

Conclusion: For Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and brain metastases, erlotinib was associated with a significantly longer OS and a more prolonged PFS and compared with gefitinib.

Citing Articles

[Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].

Zheng Y, Jiang W, Chen D, Li Y, Dai L, Huang L Zhongguo Fei Ai Za Zhi. 2021; 24(8):591-597.

PMID: 34120433 PMC: 8387645. DOI: 10.3779/j.issn.1009-3419.2021.102.22.

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

Jung H, Woo S, Lee S, Ahn J, Ahn M, Park K Transl Lung Cancer Res. 2020; 9(5):1749-1758.

PMID: 33209598 PMC: 7653133. DOI: 10.21037/tlcr-20-379.

References

Tanaka K, Hida T, Oya Y, Oguri T, Yoshida T, Shimizu J . EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma. J Thorac Oncol. 2016; 10(12):1720-5. DOI: 10.1097/JTO.0000000000000675. View

Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P . Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther. 2013; 7:1179-86. PMC: 3797237. DOI: 10.2147/DDDT.S53011. View

Lee C, Chen H, Liu H . Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations. J Clin Oncol. 2009; 28(7):e111-2. DOI: 10.1200/JCO.2009.24.0747. View

Janjigian Y, Park B, Zakowski M, Ladanyi M, Pao W, DAngelo S . Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2010; 6(3):569-75. PMC: 3778680. DOI: 10.1097/JTO.0b013e318202bffe. View

Yang J, Zhou Q, Yan H, Zhang X, Chen H, Tu H . A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017; 116(5):568-574. PMC: 5344291. DOI: 10.1038/bjc.2016.456. View

Normando S, Cruz F, Del Giglio A . Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. Anticancer Drugs. 2015; 26(9):995-1003. DOI: 10.1097/CAD.0000000000000268. View

Xu Y, Liu H, Chen J, Zhou Q . Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther. 2010; 9(8):572-82. DOI: 10.4161/cbt.9.8.11881. View

Yomo S, Oda K . Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients. Lung Cancer. 2018; 119:120-126. DOI: 10.1016/j.lungcan.2018.03.013. View

Cardona A, Arrieta O, Zapata M, Rojas L, Wills B, Reguart N . Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). Target Oncol. 2017; 12(4):513-523. DOI: 10.1007/s11523-017-0497-2. View

10.

Shen Y, Tseng G, Tu C, Chen W, Liao W, Chen W . Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer. 2017; 110:56-62. DOI: 10.1016/j.lungcan.2017.06.007. View

11.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

12.

Chang C, Lee C, Wang J . Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?. J Clin Oncol. 2017; 35(12):1374-1375. DOI: 10.1200/JCO.2016.68.5842. View

13.

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015; 26(9):1877-1883. DOI: 10.1093/annonc/mdv276. View

14.

Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S . Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009; 4(11):1415-9. DOI: 10.1097/JTO.0b013e3181b62572. View

15.

Yang C, Hung J, Tsai M, Wu K, Liu T, Chou S . The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. BMC Pharmacol Toxicol. 2017; 18(1):21. PMC: 5424380. DOI: 10.1186/s40360-017-0130-0. View

16.

Bean J, Brennan C, Shih J, Riely G, Viale A, Wang L . MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104(52):20932-7. PMC: 2409244. DOI: 10.1073/pnas.0710370104. View

17.

Fukui T, Otani S, Hataishi R, Jiang S, Nishii Y, Igawa S . Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol. 2009; 65(4):803-6. DOI: 10.1007/s00280-009-1212-5. View

18.

Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T . Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016; 34(27):3248-57. DOI: 10.1200/JCO.2015.63.4154. View

19.

Gerber N, Yamada Y, Rimner A, Shi W, Riely G, Beal K . Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014; 89(2):322-9. PMC: 5691362. DOI: 10.1016/j.ijrobp.2014.02.022. View

20.

Wu S, Shih J, Yu C, Yang P . Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. J Thorac Oncol. 2008; 3(4):451-2. DOI: 10.1097/JTO.0b013e318169e32a. View